DK2331118T3 - Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers - Google Patents

Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers Download PDF

Info

Publication number: DK2331118T3
Authority: DK; Denmark
Prior art keywords: gbm; glioblastoma; cancers; tumor; treatment
Prior art date: 2008-10-01

Application number

DK09778749.3T

Other languages

English (en)

Other versions

DK2331118T5 (en

Inventor

Oliver Schoor

Norbert Hilf

Toni Weinschenk

Steffen Walter

Claudia Trautwein

Harpreet Singh

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-01

Filing date

2009-09-28

Publication date

2017-01-09

2009-09-28 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2017-01-09 Publication of DK2331118T3 publication Critical patent/DK2331118T3/da

2017-06-19 Application granted granted Critical

2017-06-19 Publication of DK2331118T5 publication Critical patent/DK2331118T5/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Mycology (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)

DK09778749.3T 2008-10-01 2009-09-28 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers DK2331118T5 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP20080017305 EP2172211B1 (en)	2008-10-01	2008-10-01	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US10597008P	2008-10-16	2008-10-16
PCT/EP2009/006979 WO2010037513A1 (en)	2008-10-01	2009-09-28	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers

Publications (2)

Publication Number	Publication Date
DK2331118T3 true DK2331118T3 (da)	2017-01-09
DK2331118T5 DK2331118T5 (en)	2017-06-19

Family

ID=40342382

Family Applications (12)

Application Number	Title	Priority Date	Filing Date
DK08017305T DK2172211T3 (da)	2008-10-01	2008-10-01	Sammensætning af tumorassocierede peptider og relateret anticancervaccine til behandling af glioblastom (GBM) og andre cancertyper
DK08017921.1T DK2172212T3 (da)	2008-10-01	2008-10-13	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder neuronale tumorer og hjernetumorer
DK16179214.8T DK3124043T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179174.4T DK3120868T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16165070.0T DK3069728T3 (en)	2008-10-01	2009-09-28	Novel immunotherapy against several tumors including neuronal and brain tumors
DK09778750.1T DK2341927T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder neuronale tumorer og hjernetumorer
DK09778749.3T DK2331118T5 (en)	2008-10-01	2009-09-28	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
DK16179192.6T DK3120869T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179169.4T DK3132801T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179163.7T DK3106175T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179226.2T DK3120870T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179241.1T DK3111952T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer

Family Applications Before (6)

Application Number	Title	Priority Date	Filing Date
DK08017305T DK2172211T3 (da)	2008-10-01	2008-10-01	Sammensætning af tumorassocierede peptider og relateret anticancervaccine til behandling af glioblastom (GBM) og andre cancertyper
DK08017921.1T DK2172212T3 (da)	2008-10-01	2008-10-13	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder neuronale tumorer og hjernetumorer
DK16179214.8T DK3124043T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179174.4T DK3120868T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16165070.0T DK3069728T3 (en)	2008-10-01	2009-09-28	Novel immunotherapy against several tumors including neuronal and brain tumors
DK09778750.1T DK2341927T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder neuronale tumorer og hjernetumorer

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
DK16179192.6T DK3120869T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179169.4T DK3132801T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179163.7T DK3106175T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179226.2T DK3120870T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179241.1T DK3111952T3 (da)	2008-10-01	2009-09-28	Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer

Country Status (24)

Country	Link
US (19)	US8119139B2 (da)
EP (12)	EP2172211B1 (da)
JP (10)	JP5855940B2 (da)
KR (6)	KR102133402B1 (da)
CN (3)	CN102170900B (da)
AU (2)	AU2009300088B2 (da)
BR (2)	BRPI0920791B8 (da)
CA (9)	CA2936868C (da)
CY (11)	CY1116302T1 (da)
DK (12)	DK2172211T3 (da)
EA (3)	EA023378B1 (da)
ES (12)	ES2536465T3 (da)
HR (12)	HRP20201025T8 (da)
HU (11)	HUE031030T2 (da)
LT (10)	LT2172212T (da)
MX (3)	MX2011003539A (da)
NZ (4)	NZ591882A (da)
PL (12)	PL2172211T3 (da)
PT (12)	PT2172211E (da)
RS (12)	RS53782B1 (da)
SI (12)	SI2172211T1 (da)
TR (2)	TR201900852T4 (da)
UA (3)	UA110599C2 (da)
WO (2)	WO2010037514A2 (da)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8435507B2 (en)	2004-08-19	2013-05-07	University Of Maryland	Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
US7612162B2 (en)	2004-09-21	2009-11-03	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
SI2660248T1 (sl) *	2007-07-27	2015-10-30	Immatics Biotechnologies Gmbh	Nova imunoterapija proti možganskim tumorjem
ES2342506T3 (es)	2008-04-30	2010-07-07	Immatics Biotechnologies Gmbh	Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
NO2119726T3 (da)	2008-05-14	2015-05-23
PL2172211T3 (pl)	2008-10-01	2015-05-29	Immatics Biotechnologies Gmbh	Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
TW201124530A (en) *	2009-12-01	2011-07-16	Oncotherapy Science Inc	IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) *	2009-12-15	2013-03-19	Theravac Pharmaceuticals Ab	Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
GB201004551D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) *	2010-03-19	2016-11-10	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP4159226A1 (en) *	2010-08-24	2023-04-05	University of Pittsburgh - Of the Commonwealth System of Higher Education	Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2012075490A2 (en) *	2010-12-03	2012-06-07	Duke University	Anti-podoplanin antibodies and methods of use
MX2013006758A (es) *	2010-12-14	2013-08-01	Immatics Biotechnologies Gmbh	Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.
WO2013052158A2 (en) *	2011-04-26	2013-04-11	William Marsh Rice University	Targeted nanovectors and their use for treatment of brain tumors
US9889209B2 (en)	2011-09-14	2018-02-13	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
GB201120779D0 (en)	2011-12-02	2012-01-11	Immodulon Therapeutics Ltd	Cancer therapy
CN110711188A (zh)	2012-01-20	2020-01-21	德玛公司	经取代的己糖醇类用于治疗恶性肿瘤的用途
US10704021B2 (en)	2012-03-15	2020-07-07	Flodesign Sonics, Inc.	Acoustic perfusion devices
CN103372217B (zh) *	2012-04-28	2014-12-10	中国科学院深圳先进技术研究院	聚合物纳米载体制剂及其制备方法和应用
DK3536334T3 (da) *	2012-05-16	2021-09-13	Stemline Therapeutics Inc	Cancer stamcelle målrettede cancer vacciner
CN103566377A (zh) *	2012-07-18	2014-02-12	上海博笛生物科技有限公司	癌症的靶向免疫治疗
HUE057334T2 (hu) *	2013-08-05	2022-05-28	Immatics Biotechnologies Gmbh	Új immunterápia többféle tumor, például tüdõrák ellen, az NSCLC-t is beleértve
TWI777198B (zh) *	2013-08-05	2022-09-11	德商伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七）
MX2019013161A (es) *	2013-11-04	2020-02-03	Immatics Biotechnologies Gmbh	Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
CN104698059B (zh) *	2013-12-04	2017-07-21	苏州中赢医疗科技有限公司	一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en)	2013-12-20	2014-02-05	Immodulon Therapeutics Ltd	Cancer therapy
EP3092049A1 (en)	2014-01-08	2016-11-16	Flodesign Sonics Inc.	Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) *	2014-03-12	2015-03-18	국립암센터	자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
AU2015249376C1 (en)	2014-04-25	2019-10-31	2Seventy Bio, Inc.	Improved methods for manufacturing adoptive cell therapies
WO2015164759A2 (en)	2014-04-25	2015-10-29	Bluebird Bio, Inc.	Mnd promoter chimeric antigen receptors
WO2015182668A1 (ja) *	2014-05-28	2015-12-03	学校法人東京女子医科大学	膠芽腫の予測方法
JP2015227292A (ja) *	2014-05-30	2015-12-17	国立大学法人高知大学	膵がん細胞浸潤転移抑制ワクチン
SG11201610170SA (en)	2014-06-06	2017-01-27	Bluebird Bio Inc	Improved t cell compositions
JP6366379B2 (ja) *	2014-06-20	2018-08-01	キヤノン株式会社	被検体情報取得装置
CA2956002C (en)	2014-07-24	2023-06-27	Bluebird Bio, Inc.	Bcma chimeric antigen receptors
AU2014410466B2 (en) *	2014-11-06	2019-09-12	Ose Immunotherapeutics	Therapeutic multi-peptides T specific immune therapy for treatment of brain metastasis
AU2015360845B2 (en)	2014-12-12	2020-11-26	2Seventy Bio, Inc.	BCMA chimeric antigen receptors
LT3616706T (lt) *	2014-12-23	2022-02-10	Immatics Biotechnologies Gmbh	Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį
GB201501017D0 (en)	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) *	2014-12-30	2015-02-11	Immatics Biotechnologies Gmbh	Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
CR20210232A (es)	2015-03-17	2022-06-24	Immatics Biotechnologies Gmbh	NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11377651B2 (en)	2016-10-19	2022-07-05	Flodesign Sonics, Inc.	Cell therapy processes utilizing acoustophoresis
US11708572B2 (en)	2015-04-29	2023-07-25	Flodesign Sonics, Inc.	Acoustic cell separation techniques and processes
CN107810193B (zh) *	2015-05-06	2022-03-22	伊玛提克斯生物技术有限公司	用于结直肠癌(crc)和其他癌症免疫治疗的新型肽和肽组合物及其支架
GB201507719D0 (en) *	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en)	2015-06-08	2017-02-03	Applied Immune Tech Ltd	T cell receptor like antibodies having fine specificity.
EP3307307A4 (en)	2015-06-09	2019-05-01	The Board of Regents of the University of Oklahoma	COMPOSITIONS AND TREATMENTS FOR HAEMOPHILUS INFLUENZAE
PL3319635T3 (pl)	2015-06-24	2021-10-25	Immodulon Therapeutics Limited	Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL308735A (en)	2015-07-01	2024-01-01	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
RS61203B1 (sr) *	2015-07-06	2021-01-29	Immatics Biotechnologies Gmbh	Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raka jednjaka i drugih malignih tumora
MY189596A (en) *	2015-07-15	2022-02-18	Immatics Biotechnologies Gmbh	A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) *	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en)	2015-08-28	2015-10-14	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
UA125817C2 (uk)	2015-08-28	2022-06-15	Імматікс Біотекнолоджіс Гмбх	Пептид, придатний для лікування та/або діагностики раку
EP3344276B1 (en)	2015-09-03	2020-04-22	The Board of Regents of the University of Oklahoma	Peptide inhibitors of clostridium difficile tcdb toxin
EP3364985A4 (en)	2015-10-19	2019-03-27	University Of Maryland, Baltimore	METHOD FOR GENERATING MANIPULATED DENDRITIC CELL LINES FROM HUMAN PRIMARY BLOOD
US11479755B2 (en)	2015-12-07	2022-10-25	2Seventy Bio, Inc.	T cell compositions
GB201521746D0 (en) *	2015-12-10	2016-01-27	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
IL298653A (en) *	2015-12-11	2023-01-01	Immatics Biotechnologies Gmbh	New peptides and a combination of peptides for use in immunotherapy against several types of cancer
EP3389630B1 (en)	2015-12-16	2023-11-08	Gritstone bio, Inc.	Neoantigen identification, manufacture, and use
US10604759B2 (en)	2016-01-15	2020-03-31	City Of Hope	Targeting glioblastoma stem cells through the TLX-TET3 axis
GB201603568D0 (en) *	2016-03-01	2016-04-13	Immatics Biotechnologies Gmbh	Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) *	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
CN105664134B (zh) *	2016-03-13	2019-04-26	浙江药苑生物科技有限公司	一种用于治疗骨癌的药物组合物
GB201604490D0 (en) *	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides combination of peptides for use in immunotherapy against cancers
HUE060725T2 (hu)	2016-03-16	2023-04-28	Immatics Biotechnologies Gmbh	Transzfektált T-sejtek és T-sejt receptorok daganatok ellen alkalmazott immunterápiában történõ használatra
GB201604494D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
KR102411975B1 (ko) *	2016-04-06	2022-06-22	이매틱스 바이오테크놀로지스 게엠베하	Aml 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
US11214789B2 (en)	2016-05-03	2022-01-04	Flodesign Sonics, Inc.	Concentration and washing of particles with acoustics
WO2017194170A1 (en) *	2016-05-13	2017-11-16	Biontech Rna Pharmaceuticals Gmbh	Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko)	2016-06-30	2018-07-25	영남대학교 산학협력단	아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
FI3518948T3 (fi) *	2016-10-03	2023-07-18	Ottawa Hospital Res Inst	Koostumuksia ja menetelmiä onkolyyttisten rna-virusten kasvun, leviämisen sekä onkolyyttisen ja immunoterapeuttisen tehokkuuden tehostamiseksi
JP7093346B2 (ja)	2016-11-04	2022-06-29	２セブンティバイオインコーポレイテッド	抗ｂｃｍａｃａｒｔ細胞組成物
EP4317432A3 (en)	2016-12-08	2024-04-17	Immatics Biotechnologies GmbH	T cell receptors with improved pairing
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
WO2018119114A1 (en)	2016-12-22	2018-06-28	Cue Biopharma, Inc.	T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018127787A1 (en)	2017-01-06	2018-07-12	Eutilex Co., Ltd.	Anti-human 4-1 bb antibodies and use thereof
GB201702863D0 (en) *	2017-02-22	2017-04-05	Evox Therapeutics Ltd	Improved loading of EVs with therapeutic proteins
US20180248175A1 (en) *	2017-02-28	2018-08-30	Lyten, Inc.	Mixed allotrope particulate carbon films and carbon fiber mats
TW201907937A (zh) *	2017-05-08	2019-03-01	美商葛利史東腫瘤科技公司	阿爾法病毒新抗原載體
CN107058596A (zh) *	2017-06-19	2017-08-18	上海市第十人民医院	一种与恶性胶质瘤诊断相关的标志物及其应用
CN107034305A (zh) *	2017-06-19	2017-08-11	上海市第十人民医院	恶性胶质瘤的一种诊断标志物
JP7227237B2 (ja)	2017-10-10	2023-02-21	グリットストーンバイオインコーポレイテッド	ホットスポットを利用した新生抗原の特定
CN111630602A (zh)	2017-11-22	2020-09-04	磨石肿瘤生物技术公司	减少新抗原的接合表位呈递
EP3724327A4 (en) *	2017-12-14	2022-01-12	EZY Biotech LLC	SUBJECT-SPECIFIC TUMOR INHIBITION CELLS AND THEIR USE
JP2021507561A (ja)	2017-12-14	2021-02-22	フロデザインソニックス，インク．ＦｌｏｄｅｓｉｇｎＳｏｎｉｃｓ，Ｉｎｃ．	音響トランスデューサドライバ及びコントローラ
SI3773689T1 (sl) *	2018-04-11	2023-02-28	Enterome S.A.	Antigenski peptidi za preprečevanje in zdravljenje raka
CN108715832B (zh) *	2018-06-01	2020-11-10	段海峰	一种抑制肿瘤生长的间充质干细胞及制备方法和应用
WO2020014471A1 (en)	2018-07-11	2020-01-16	The Brigham And Women's Hospital, Inc.	Methods and compositions for delivery of agents across the blood-brain barrier
WO2020110154A1 (en) *	2018-11-30	2020-06-04	Bharat Biotech International Limited	A chimeric therapeutic vaccine
RU2706554C1 (ru) *	2018-12-13	2019-11-19	Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ	Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) *	2019-02-22	2021-09-17	上海尚泰生物技术有限公司	一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
BR112021018854A2 (pt)	2019-03-29	2021-11-30	Intervet Int Bv	Estabilização de bactérias mollicutes vivas em uma composição líquida
EP4600650A3 (en) *	2019-04-05	2025-11-26	Earli Inc.	Improved methods and compositions for synthetic biomarkers
CN114207675A (zh)	2019-05-28	2022-03-18	佩治人工智能公司	用于数字病理学的用于处理图像以针对所处理的图像制备载片的系统和方法
IL288283B2 (en)	2019-05-30	2025-05-01	Gritstone Bio Inc	Modified adenovirus
CN110579457B (zh) *	2019-09-20	2021-11-02	郑州大学第一附属医院	波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) *	2019-11-18	2022-06-24	杨小骏	一种抑制胶质瘤的短肽及其应用
US11981705B2 (en) *	2020-01-10	2024-05-14	The Brigham And Women's Hospital, Inc.	Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
JP7777872B2 (ja) *	2020-02-24	2025-12-01	ザリージェンツオブザユニバーシティオブカリフォルニア	細胞ベースの治療を脳にホーミング、ブロック及び送達するための脳特異的抗原の使用
CN113318225B (zh) *	2020-02-28	2024-01-19	无锡派列博生物医药科技有限公司	肿瘤免疫增强剂及其制法和应用
CN113388006A (zh) *	2020-03-18	2021-09-14	北京鼎成肽源生物技术有限公司	一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
EP4127188A4 (en)	2020-03-31	2024-08-21	Walking Fish Therapeutics	MODIFIED B CELLS AND METHODS OF USE THEREOF
CA3173480A1 (en) *	2020-03-31	2021-10-07	Kathleen Boyle	Modified b cells and methods of use thereof
AU2021272895A1 (en)	2020-05-12	2022-09-22	Cue Biopharma, Inc.	Multimeric T-cell modulatory polypeptides and methods of use thereof
IL300026A (en)	2020-08-06	2023-03-01	Gritstone Bio Inc	Multiepitope vaccine cassettes
KR102711471B1 (ko)	2020-08-14	2024-09-30	서울대학교산학협력단	B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
CA3190707A1 (en) *	2020-08-28	2022-03-03	Torigen Pharmaceuticals, Inc.	Immune memory enhanced preparations and uses thereof
CN116710115A (zh)	2020-11-20	2023-09-05	思维疗法股份有限公司	用于优化的肽疫苗的组合物和方法
US11421015B2 (en)	2020-12-07	2022-08-23	Think Therapeutics, Inc.	Method of compact peptide vaccines using residue optimization
US11058751B1 (en)	2020-11-20	2021-07-13	Think Therapeutics, Inc.	Compositions for optimized RAS peptide vaccines
US20220319638A1 (en) *	2021-03-09	2022-10-06	Bostongene Corporation	Predicting response to treatments in patients with clear cell renal cell carcinoma
US11464842B1 (en)	2021-04-28	2022-10-11	Think Therapeutics, Inc.	Compositions and method for optimized peptide vaccines using residue optimization
US20250235517A1 (en) *	2022-03-30	2025-07-24	Iogenetics, Llc	Tumor-associated antigens in brain tumors
PL441229A1 (pl) *	2022-05-19	2023-11-20	Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk	Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
CN120272531B (zh) *	2025-06-10	2025-08-19	鼐济医药科技(杭州)有限公司	一种基于aav介导免疫微环境的脑胶质瘤动物模型构建方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
BR7908410A (pt)	1978-12-22	1980-09-09	Biogen Nv	Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en)	1986-06-27	1990-01-30	The Administrators Of The Tulane Educational Fund	Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) *	1988-04-12	1994-08-16	Massachusetts Institute Of Technology	DNA encoding nestin protein
GB2267257A (en)	1992-05-14	1993-12-01	Ford Motor Co	A vehicle load compartment liner.
KR100235089B1 (en)	1992-05-14	1999-12-15	Mitsui Chemicals Inc	Ptp or blister packaging articles and packaging material therefor
DE69420137T2 (de)	1993-06-03	1999-12-23	Therapeutic Antibodies, Inc.	Herstellung von antikörperfragmenten
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
WO1997026328A1 (en)	1996-01-17	1997-07-24	Imperial College Innovations Limited	Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en)	1996-03-11	1998-12-15	Duke University	Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
IL120561A0 (en) *	1996-04-24	1997-07-13	Akzo Nobel Nv	Peptides suitable for use in immunosuppressive therapy
JP2002513381A (ja) *	1996-07-22	2002-05-08	ザロックフェラーユニバーシティー	ＨＴＬＶ―Ｉ感染およびＨＴＬＶ―ＩＩ感染を予防するためのｅｎｖ―糖タンパク質ワクチン
AU6240798A (en)	1997-01-15	1998-08-07	Zymogenetics Inc.	Zppar6, human tailless nuclear hormone receptor (tlx receptor)
EP0910641A1 (en) *	1997-02-13	1999-04-28	Smithkline Beecham Plc	Neural cell adhesion molecule splicing variants
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1044263A2 (en) *	1997-12-02	2000-10-18	Medarex, Inc.	CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
US7258860B2 (en) *	1998-03-18	2007-08-21	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
AU3762699A (en) *	1998-04-27	1999-11-16	Pacific Northwest Cancer Foundation	(nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US20030082586A1 (en) *	1999-06-29	2003-05-01	Millennium Pharmaceuticals, Inc.	Antibodies having diagnostic, preventive, therapeutic, and other uses
US20020090672A1 (en) *	2000-01-31	2002-07-11	Rosen Craig A.	Nucleic acids, proteins, and antibodies
WO2001055173A2 (en) *	2000-01-31	2001-08-02	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
CA2404489A1 (en)	2000-03-27	2001-10-04	Technion Research And Development Foundation Ltd.	Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en)	2003-03-26	2004-09-30	Technion Research & Development Foundation Ltd.	Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2002020036A1 (de) *	2000-09-06	2002-03-14	Mueller Friederike	Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
US7919467B2 (en) *	2000-12-04	2011-04-05	Immunotope, Inc.	Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1356048A2 (en) *	2000-12-04	2003-10-29	Argonex Pharmaceuticals	Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1379879A2 (en) *	2000-12-08	2004-01-14	Oxford GlycoSciences (UK) Limited	Diagnosis and treatment of alzheimer's disease
US20030109434A1 (en) *	2001-03-19	2003-06-12	Corixa Corporation	Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) *	2001-11-30	2003-05-30	Christopher Gillberg	Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en)	2001-12-21	2003-07-08	Kloeckner Pentaplast Of America, Inc.	Three part high moisture barrier for packages
US7892559B2 (en) *	2002-01-30	2011-02-22	Survac Aps	Survivin-derived peptides and use thereof
US6992176B2 (en)	2002-02-13	2006-01-31	Technion Research & Development Foundation Ltd.	Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en)	2002-02-20	2006-04-26	Dyax Corp	MHC-PEPTIDE COMPLEX BINDING LIGANDS
AU2003258134A1 (en) *	2002-08-09	2004-02-25	Applera Corporation	Lung cancer target proteins and use thereof
JP4721633B2 (ja) *	2002-10-11	2011-07-13	財団法人癌研究会	血小板凝集促進活性を有する物質
AU2003298984A1 (en) *	2002-12-27	2004-08-23	Shenzhen Tsinghua Yuanxing Bio-Pharm Science And Technology Co., Ltd.	Method of preparing a vaccine and anti-tumor vaccines
US20060241166A1 (en)	2003-04-04	2006-10-26	Pharmacyclica, Inc.	Sapphyrins and uses thereof
US7273980B2 (en)	2004-01-13	2007-09-25	Wardle Scott A	Position and velocity transducer using a phonograph disc and turntable
WO2005071075A1 (ja) *	2004-01-23	2005-08-04	Green Peptide Co., Ltd.	上皮細胞増殖因子受容体（egfr）由来ペプチド
DE102004026135A1 (de) *	2004-05-25	2006-01-05	Immatics Biotechnologies Gmbh	An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006026569A2 (en) *	2004-08-27	2006-03-09	Northeastern University	Comprehensive characterization of complex proteins at trace levels
PL1642905T3 (pl) *	2004-10-02	2009-04-30	Immatics Biotechnologies Gmbh	Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
CN101072875B (zh) *	2004-12-07	2011-05-18	东丽株式会社	新型癌抗原肽及其用途
KR100809410B1 (ko) *	2005-07-06	2008-03-05	주식회사 브레인가드	줄기세포 분화 유도용 조성물 및 그의 용도
EP1760089B1 (en) *	2005-09-05	2009-08-19	Immatics Biotechnologies GmbH	Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
SI1806359T1 (sl)	2005-09-05	2010-06-30	Immatics Biotechnologies Gmbh	S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II
US20070099251A1 (en)	2005-10-17	2007-05-03	Institute For Systems Biology	Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) *	2005-12-06	2007-10-25	Keller Lorraine H	Immunogens in cancer stem cells
WO2007072494A1 (en)	2005-12-23	2007-06-28	Naik Praful Ramchandra	Metallized packaging blister container
US9487574B2 (en) *	2006-09-21	2016-11-08	Vaxil Biotherapeutics Ltd.	Antigen specific multi epitope vaccines
EP2084267B1 (en) *	2006-09-26	2018-04-11	Cedars-Sinai Medical Center	Cancer stem cell antigen vaccines and methods
WO2008109757A2 (en) *	2007-03-06	2008-09-12	Iterative Therapeutics, Inc.	Methods and compositions involving polymeric immunoglobulin fusion proteins
WO2009125394A1 (en) *	2008-04-09	2009-10-15	Technion Research & Development Foundation Ltd.	Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko)	2008-04-24	2012-09-20	이매틱스 바이오테크놀로지스 게엠베하	백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
ES2342506T3 (es) *	2008-04-30	2010-07-07	Immatics Biotechnologies Gmbh	Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
PL2172211T3 (pl) *	2008-10-01	2015-05-29	Immatics Biotechnologies Gmbh	Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
GB201004551D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en)	2010-12-15	2011-01-26	Immatics Biotechnologies Gmbh	Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
JP6622222B2 (ja) *	2014-05-28	2019-12-18	ノノインコーポレイテッド	Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
BR112018070873A2 (pt) *	2016-04-21	2019-02-05	Immatics Biotechnologies Gmbh	imunoterapia contra melanoma e outros cânceres
US12221465B2 (en) *	2017-09-06	2025-02-11	California Institute Of Technology	Signaling and antigen-presenting bifunctional receptors (SABR)

2008
- 2008-10-01 PL PL08017305T patent/PL2172211T3/pl unknown
- 2008-10-01 DK DK08017305T patent/DK2172211T3/da active
- 2008-10-01 EP EP20080017305 patent/EP2172211B1/en active Active
- 2008-10-01 SI SI200831373T patent/SI2172211T1/sl unknown
- 2008-10-01 PT PT80173057T patent/PT2172211E/pt unknown
- 2008-10-01 ES ES08017305.7T patent/ES2536465T3/es active Active
- 2008-10-01 RS RS20150094A patent/RS53782B1/sr unknown
- 2008-10-13 LT LTEP08017921.1T patent/LT2172212T/lt unknown
- 2008-10-13 PT PT80179211T patent/PT2172212T/pt unknown
- 2008-10-13 ES ES08017921.1T patent/ES2607460T3/es active Active
- 2008-10-13 SI SI200831695A patent/SI2172212T1/sl unknown
- 2008-10-13 HU HUE08017921A patent/HUE031030T2/en unknown
- 2008-10-13 PL PL08017921T patent/PL2172212T3/pl unknown
- 2008-10-13 EP EP08017921.1A patent/EP2172212B1/en active Active
- 2008-10-13 DK DK08017921.1T patent/DK2172212T3/da active
- 2008-10-13 RS RS20161019A patent/RS55543B1/sr unknown
2009
- 2009-09-28 PL PL16179214T patent/PL3124043T3/pl unknown
- 2009-09-28 PT PT97787501T patent/PT2341927T/pt unknown
- 2009-09-28 CA CA2936868A patent/CA2936868C/en active Active
- 2009-09-28 RS RS20200085A patent/RS60006B1/sr unknown
- 2009-09-28 PT PT161791744T patent/PT3120868T/pt unknown
- 2009-09-28 LT LTEP09778749.3T patent/LT2331118T/lt unknown
- 2009-09-28 PT PT161792262T patent/PT3120870T/pt unknown
- 2009-09-28 DK DK16179214.8T patent/DK3124043T3/da active
- 2009-09-28 PL PL16179192T patent/PL3120869T3/pl unknown
- 2009-09-28 ES ES16179226T patent/ES2802227T3/es active Active
- 2009-09-28 LT LTEP16179174.4T patent/LT3120868T/lt unknown
- 2009-09-28 KR KR1020187021349A patent/KR102133402B1/ko active Active
- 2009-09-28 LT LTEP16179214.8T patent/LT3124043T/lt unknown
- 2009-09-28 EP EP16179241.1A patent/EP3111952B1/en active Active
- 2009-09-28 KR KR1020167022929A patent/KR101883426B1/ko active Active
- 2009-09-28 DK DK16179174.4T patent/DK3120868T3/da active
- 2009-09-28 SI SI200932034T patent/SI3132801T1/sl unknown
- 2009-09-28 ES ES16179169T patent/ES2770090T3/es active Active
- 2009-09-28 CA CA2936887A patent/CA2936887C/en active Active
- 2009-09-28 ES ES16179241T patent/ES2708654T3/es active Active
- 2009-09-28 PL PL16179241T patent/PL3111952T3/pl unknown
- 2009-09-28 SI SI200931921T patent/SI3069728T1/sl unknown
- 2009-09-28 DK DK16165070.0T patent/DK3069728T3/en active
- 2009-09-28 KR KR1020117010000A patent/KR101687840B1/ko not_active Expired - Fee Related
- 2009-09-28 EP EP09778749.3A patent/EP2331118B1/en active Active
- 2009-09-28 HU HUE16179226A patent/HUE049364T2/hu unknown
- 2009-09-28 CA CA2936920A patent/CA2936920C/en active Active
- 2009-09-28 UA UAA201103611A patent/UA110599C2/uk unknown
- 2009-09-28 CA CA2739387A patent/CA2739387C/en active Active
- 2009-09-28 NZ NZ591882A patent/NZ591882A/xx not_active IP Right Cessation
- 2009-09-28 ES ES16179192T patent/ES2819244T3/es active Active
- 2009-09-28 CN CN200980139419.2A patent/CN102170900B/zh active Active
- 2009-09-28 SI SI200932083T patent/SI3120869T1/sl unknown
- 2009-09-28 DK DK09778750.1T patent/DK2341927T3/da active
- 2009-09-28 HR HRP20201025TT patent/HRP20201025T8/hr unknown
- 2009-09-28 PL PL16179226T patent/PL3120870T3/pl unknown
- 2009-09-28 RS RS20181585A patent/RS58229B1/sr unknown
- 2009-09-28 MX MX2011003539A patent/MX2011003539A/es active IP Right Grant
- 2009-09-28 MX MX2012012047A patent/MX338294B/es unknown
- 2009-09-28 EP EP16179169.4A patent/EP3132801B1/en active Active
- 2009-09-28 RS RS20160553A patent/RS55043B1/sr unknown
- 2009-09-28 EP EP16179174.4A patent/EP3120868B1/en active Active
- 2009-09-28 HU HUE16179163A patent/HUE049367T2/hu unknown
- 2009-09-28 PT PT161791694T patent/PT3132801T/pt unknown
- 2009-09-28 CA CA2936870A patent/CA2936870C/en active Active
- 2009-09-28 PT PT97787493T patent/PT2331118T/pt unknown
- 2009-09-28 ES ES16179163T patent/ES2802226T3/es active Active
- 2009-09-28 RS RS20200512A patent/RS60338B1/sr unknown
- 2009-09-28 HR HRP20170115TT patent/HRP20170115T1/hr unknown
- 2009-09-28 WO PCT/EP2009/006980 patent/WO2010037514A2/en not_active Ceased
- 2009-09-28 UA UAA201500916A patent/UA125277C2/uk unknown
- 2009-09-28 ES ES16179214T patent/ES2788129T3/es active Active
- 2009-09-28 HU HUE16179169A patent/HUE047365T2/hu unknown
- 2009-09-28 EP EP16179192.6A patent/EP3120869B1/en active Active
- 2009-09-28 PT PT161792148T patent/PT3124043T/pt unknown
- 2009-09-28 LT LTEP16179192.6T patent/LT3120869T/lt unknown
- 2009-09-28 PT PT161791926T patent/PT3120869T/pt unknown
- 2009-09-28 LT LTEP16179163.7T patent/LT3106175T/lt unknown
- 2009-09-28 BR BRPI0920791A patent/BRPI0920791B8/pt not_active IP Right Cessation
- 2009-09-28 TR TR2019/00852T patent/TR201900852T4/tr unknown
- 2009-09-28 RS RS20200973A patent/RS60656B1/sr unknown
- 2009-09-28 MX MX2011003540A patent/MX2011003540A/es active IP Right Grant
- 2009-09-28 LT LTEP16179226.2T patent/LT3120870T/lt unknown
- 2009-09-28 SI SI200932064T patent/SI3120870T1/sl unknown
- 2009-09-28 DK DK09778749.3T patent/DK2331118T5/da active
- 2009-09-28 WO PCT/EP2009/006979 patent/WO2010037513A1/en not_active Ceased
- 2009-09-28 LT LTEP16179241.1T patent/LT3111952T/lt unknown
- 2009-09-28 EP EP09778750.1A patent/EP2341927B1/en active Active
- 2009-09-28 UA UAA201103612A patent/UA103202C2/ru unknown
- 2009-09-28 KR KR1020227013879A patent/KR20220058655A/ko not_active Ceased
- 2009-09-28 PT PT161791637T patent/PT3106175T/pt unknown
- 2009-09-28 EP EP16165070.0A patent/EP3069728B1/en active Active
- 2009-09-28 CA CA2936982A patent/CA2936982C/en active Active
- 2009-09-28 EP EP16179163.7A patent/EP3106175B1/en active Active
- 2009-09-28 NZ NZ624533A patent/NZ624533A/en not_active IP Right Cessation
- 2009-09-28 HR HRP20160915TT patent/HRP20160915T1/hr unknown
- 2009-09-28 HU HUE09778749A patent/HUE030296T2/en unknown
- 2009-09-28 ES ES09778750.1T patent/ES2584245T3/es active Active
- 2009-09-28 CA CA2936924A patent/CA2936924C/en active Active
- 2009-09-28 LT LTEP16179169.4T patent/LT3132801T/lt unknown
- 2009-09-28 SI SI200932065T patent/SI3120868T1/sl unknown
- 2009-09-28 ES ES16179174T patent/ES2804723T3/es active Active
- 2009-09-28 BR BRPI0920759A patent/BRPI0920759A2/pt not_active Application Discontinuation
- 2009-09-28 DK DK16179192.6T patent/DK3120869T3/da active
- 2009-09-28 DK DK16179169.4T patent/DK3132801T3/da active
- 2009-09-28 NZ NZ603016A patent/NZ603016A/en not_active IP Right Cessation
- 2009-09-28 JP JP2011529472A patent/JP5855940B2/ja not_active Expired - Fee Related
- 2009-09-28 ES ES16165070T patent/ES2710608T3/es active Active
- 2009-09-28 LT LTEP16165070.0T patent/LT3069728T/lt unknown
- 2009-09-28 CA CA2739384A patent/CA2739384C/en not_active Expired - Fee Related
- 2009-09-28 PT PT16179241T patent/PT3111952T/pt unknown
- 2009-09-28 DK DK16179163.7T patent/DK3106175T3/da active
- 2009-09-28 EA EA201100587A patent/EA023378B1/ru unknown
- 2009-09-28 SI SI200931902T patent/SI3111952T1/sl unknown
- 2009-09-28 EP EP16179226.2A patent/EP3120870B1/en active Active
- 2009-09-28 CN CN201610831523.XA patent/CN106986919A/zh active Pending
- 2009-09-28 AU AU2009300088A patent/AU2009300088B2/en not_active Ceased
- 2009-09-28 CN CN200980139420.5A patent/CN102170901B/zh not_active Expired - Fee Related
- 2009-09-28 DK DK16179226.2T patent/DK3120870T3/da active
- 2009-09-28 PL PL16165070T patent/PL3069728T3/pl unknown
- 2009-09-28 PL PL16179174T patent/PL3120868T3/pl unknown
- 2009-09-28 RS RS20200693A patent/RS60386B1/sr unknown
- 2009-09-28 HU HUE09778750A patent/HUE029360T2/en unknown
- 2009-09-28 JP JP2011529471A patent/JP5753783B2/ja not_active Expired - Fee Related
- 2009-09-28 PT PT16165070T patent/PT3069728T/pt unknown
- 2009-09-28 PL PL09778750.1T patent/PL2341927T3/pl unknown
- 2009-09-28 KR KR1020207019579A patent/KR102392070B1/ko active Active
- 2009-09-28 RS RS20161160A patent/RS55531B1/sr unknown
- 2009-09-28 RS RS20200692A patent/RS60385B1/sr unknown
- 2009-09-28 SI SI200931573A patent/SI2331118T1/sl unknown
- 2009-09-28 SI SI200932063T patent/SI3106175T1/sl unknown
- 2009-09-28 HU HUE16165070A patent/HUE041446T2/hu unknown
- 2009-09-28 CA CA2936869A patent/CA2936869C/en active Active
- 2009-09-28 KR KR1020117010003A patent/KR101756488B1/ko not_active Expired - Fee Related
- 2009-09-28 AU AU2009300087A patent/AU2009300087B2/en not_active Ceased
- 2009-09-28 ES ES09778749.3T patent/ES2612466T3/es active Active
- 2009-09-28 PL PL16179163T patent/PL3106175T3/pl unknown
- 2009-09-28 RS RS20190118A patent/RS58443B1/sr unknown
- 2009-09-28 NZ NZ591855A patent/NZ591855A/xx not_active IP Right Cessation
- 2009-09-28 HU HUE16179214A patent/HUE051030T2/hu unknown
- 2009-09-28 TR TR2019/00809T patent/TR201900809T4/tr unknown
- 2009-09-28 PL PL16179169T patent/PL3132801T3/pl unknown
- 2009-09-28 HU HUE16179241A patent/HUE042115T2/hu unknown
- 2009-09-28 SI SI200931464A patent/SI2341927T1/sl unknown
- 2009-09-28 EP EP16179214.8A patent/EP3124043B1/en active Active
- 2009-09-28 HU HUE16179174A patent/HUE049366T2/hu unknown
- 2009-09-28 EA EA201401104A patent/EA032437B1/ru unknown
- 2009-09-28 PL PL09778749T patent/PL2331118T3/pl unknown
- 2009-09-28 HU HUE16179192A patent/HUE050428T2/hu unknown
- 2009-09-28 EA EA201100586A patent/EA023013B1/ru unknown
- 2009-09-28 RS RS20200691A patent/RS60381B1/sr unknown
- 2009-09-28 SI SI200932056T patent/SI3124043T1/sl unknown
- 2009-09-28 DK DK16179241.1T patent/DK3111952T3/da active
- 2009-10-01 US US12/571,776 patent/US8119139B2/en active Active
- 2009-10-01 US US12/571,602 patent/US8318677B2/en active Active
2012
- 2012-01-09 US US13/346,598 patent/US8961985B2/en active Active
- 2012-08-17 US US13/588,206 patent/US8653035B2/en active Active
2013
- 2013-03-15 US US13/841,013 patent/US8895514B2/en active Active
2014
- 2014-06-19 JP JP2014126001A patent/JP5883476B2/ja not_active Expired - Fee Related
- 2014-12-05 US US14/562,156 patent/US10227381B2/en active Active
2015
- 2015-02-12 CY CY20151100139T patent/CY1116302T1/el unknown
- 2015-02-26 HR HRP20150223TT patent/HRP20150223T8/hr unknown
- 2015-10-08 JP JP2015200021A patent/JP6150859B2/ja active Active
2016
- 2016-02-05 JP JP2016021002A patent/JP6214066B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136517A patent/JP6294913B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136518A patent/JP6294914B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136515A patent/JP6367266B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136516A patent/JP2017029135A/ja active Pending
- 2016-07-11 JP JP2016136519A patent/JP6297632B2/ja not_active Expired - Fee Related
- 2016-08-02 US US15/226,126 patent/US10919931B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,161 patent/US10941181B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,206 patent/US10047124B2/en active Active
- 2016-08-02 US US15/226,098 patent/US10906936B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,081 patent/US10046037B2/en active Active
- 2016-08-02 US US15/226,038 patent/US10100085B2/en active Active
- 2016-08-02 US US15/226,002 patent/US10047123B2/en active Active
- 2016-08-02 CY CY20161100759T patent/CY1119744T1/el unknown
- 2016-11-15 HR HRP20161504TT patent/HRP20161504T1/hr unknown
2017
- 2017-01-26 CY CY20171100124T patent/CY1118702T1/el unknown
- 2017-06-30 US US15/638,806 patent/US9993540B2/en active Active
2018
- 2018-09-19 US US16/136,008 patent/US20190010190A1/en not_active Abandoned
- 2018-12-18 HR HRP20182151TT patent/HRP20182151T1/hr unknown
- 2018-12-28 CY CY181101403T patent/CY1121098T1/el unknown
2019
- 2019-01-31 HR HRP20190202TT patent/HRP20190202T1/hr unknown
- 2019-02-12 CY CY20191100182T patent/CY1121258T1/el unknown
2020
- 2020-01-23 HR HRP20200110TT patent/HRP20200110T1/hr unknown
- 2020-01-28 CY CY20201100073T patent/CY1122677T1/el unknown
- 2020-05-05 HR HRP20200722TT patent/HRP20200722T1/hr unknown
- 2020-05-15 CY CY20201100449T patent/CY1122913T1/el unknown
- 2020-06-19 HR HRP20200988TT patent/HRP20200988T1/hr unknown
- 2020-06-26 CY CY20201100594T patent/CY1123089T1/el unknown
- 2020-06-26 HR HRP20201015TT patent/HRP20201015T8/hr unknown
- 2020-06-30 CY CY20201100606T patent/CY1123098T1/el unknown
- 2020-07-03 CY CY20201100613T patent/CY1123113T1/el unknown
- 2020-08-06 HR HRP20201228TT patent/HRP20201228T1/hr unknown
- 2020-10-19 CY CY20201100984T patent/CY1123526T1/el unknown
2021
- 2021-04-23 US US17/238,840 patent/US11136352B2/en active Active
- 2021-04-23 US US17/238,787 patent/US12234298B2/en active Active
- 2021-04-23 US US17/238,806 patent/US12221493B2/en active Active
- 2021-07-23 US US17/384,152 patent/US11208434B2/en active Active

Also Published As

Publication number	Publication date
DK3124043T3 (da)	2020-05-04
ES2802227T3 (es)	2021-01-18
HRP20160915T1 (hr)	2016-10-07
HRP20161504T1 (hr)	2016-12-30
RS58229B1 (sr)	2019-03-29
SI3069728T1 (sl)	2019-03-29
HUE031030T2 (en)	2017-06-28
HUE042115T2 (hu)	2019-06-28
US20100158931A1 (en)	2010-06-24
HRP20170115T1 (hr)	2017-03-24
KR20180088494A (ko)	2018-08-03
CA2936924A1 (en)	2010-04-08
CA2936869A1 (en)	2010-04-08
NZ591882A (en)	2012-12-21
LT3132801T (lt)	2020-02-10
JP5753783B2 (ja)	2015-07-22
SI3120868T1 (sl)	2020-08-31
CY1118702T1 (el)	2017-07-12
EP3069728A1 (en)	2016-09-21
CA2936920C (en)	2019-12-03
US20210261614A1 (en)	2021-08-26
HUE049364T2 (hu)	2020-09-28
JP2014239681A (ja)	2014-12-25
PT3120869T (pt)	2020-09-22
EP3120869B1 (en)	2020-07-22
HUE030296T2 (en)	2017-04-28
NZ624533A (en)	2015-09-25
EP3120869A1 (en)	2017-01-25
DK3132801T3 (da)	2020-02-10
LT3120869T (lt)	2020-11-10
EP2172211B1 (en)	2014-12-03
JP2016047825A (ja)	2016-04-07
CN102170900A (zh)	2011-08-31
EP3120870B1 (en)	2020-04-01
CA2936920A1 (en)	2010-04-08
US20130309193A1 (en)	2013-11-21
PT3120870T (pt)	2020-07-01
HRP20201015T8 (hr)	2022-01-21
US10941181B2 (en)	2021-03-09
KR20110082155A (ko)	2011-07-18
CN102170901B (zh)	2015-01-07
DK3120869T3 (da)	2020-08-10
US10100085B2 (en)	2018-10-16
SI3120869T1 (sl)	2020-10-30
EP2172212B1 (en)	2016-10-05
HRP20201228T1 (hr)	2021-02-05
PT3106175T (pt)	2020-07-01
DK3111952T3 (da)	2019-01-28
US20160355550A1 (en)	2016-12-08
HRP20200110T1 (hr)	2020-05-15
CY1121098T1 (el)	2019-12-11
CA2936982C (en)	2019-12-03
US8895514B2 (en)	2014-11-25
DK3106175T3 (da)	2020-06-22
PT3132801T (pt)	2020-02-04
TR201900809T4 (tr)	2019-02-21
JP6367266B2 (ja)	2018-08-01
HRP20200988T1 (hr)	2020-10-16
DK2172212T3 (da)	2016-12-19
CA2936868A1 (en)	2010-04-08
HUE029360T2 (en)	2017-02-28
WO2010037514A2 (en)	2010-04-08
SI2341927T1 (sl)	2016-08-31
UA125277C2 (uk)	2022-02-16
ES2804723T3 (es)	2021-02-09
ES2536465T3 (es)	2015-05-25
EP3106175A1 (en)	2016-12-21
PT3124043T (pt)	2020-05-12
CA2936887A1 (en)	2010-04-08
JP6294914B2 (ja)	2018-03-14
CA2936870C (en)	2019-11-26
CA2936887C (en)	2019-11-12
EP2341927A2 (en)	2011-07-13
BRPI0920791B8 (pt)	2022-02-15
LT2172212T (lt)	2016-11-10
EP3124043A1 (en)	2017-02-01
US12234298B2 (en)	2025-02-25
CY1122913T1 (el)	2021-10-29
JP6297632B2 (ja)	2018-03-20
RS58443B1 (sr)	2019-04-30
MX2011003540A (es)	2011-06-20
US11208434B2 (en)	2021-12-28
EA201401104A1 (ru)	2015-05-29
US20210238227A1 (en)	2021-08-05
PL2331118T3 (pl)	2017-05-31
RS55543B1 (sr)	2017-05-31
US20210253637A1 (en)	2021-08-19
AU2009300087B2 (en)	2014-09-04
EP3124043B1 (en)	2020-04-29
JP6294913B2 (ja)	2018-03-14
RS60338B1 (sr)	2020-07-31
CA2739384A1 (en)	2010-04-08
US11136352B2 (en)	2021-10-05
LT2331118T (lt)	2016-12-27
PL2172212T3 (pl)	2017-04-28
CY1119744T1 (el)	2018-06-27
ES2770090T3 (es)	2020-06-30
PT2172211E (pt)	2015-03-09
EP3132801A1 (en)	2017-02-22
US20130004456A1 (en)	2013-01-03
RS55531B1 (sr)	2017-05-31
RS53782B1 (sr)	2015-06-30
WO2010037513A1 (en)	2010-04-08
PT2331118T (pt)	2017-02-06
EP3106175B1 (en)	2020-04-01
CA2936870A1 (en)	2010-04-08
AU2009300087A1 (en)	2010-04-08
AU2009300088B2 (en)	2014-09-04
PL3120870T3 (pl)	2020-07-27
SI3111952T1 (sl)	2019-01-31
HRP20182151T1 (hr)	2019-02-08
EP2331118B1 (en)	2016-10-26
CA2936924C (en)	2019-07-16
HUE049366T2 (hu)	2020-09-28
US20160376317A1 (en)	2016-12-29
AU2009300088A1 (en)	2010-04-08
HUE049367T2 (hu)	2020-09-28
LT3069728T (lt)	2019-02-11
US20110002963A1 (en)	2011-01-06
ES2710608T3 (es)	2019-04-26
TR201900852T4 (tr)	2019-02-21
MX338294B (es)	2016-04-11
LT3106175T (lt)	2020-08-10
US10046037B2 (en)	2018-08-14
US9993540B2 (en)	2018-06-12
US20170326217A1 (en)	2017-11-16
SI2172212T1 (sl)	2016-12-30
EP2331118A1 (en)	2011-06-15
PT3069728T (pt)	2019-02-13
HRP20150223T1 (hr)	2015-06-05
HUE051030T2 (hu)	2021-01-28
US8961985B2 (en)	2015-02-24
JP6150859B2 (ja)	2017-06-21
DK2172211T3 (da)	2015-02-16
DK3120868T3 (da)	2020-06-22
HUE047365T2 (hu)	2020-04-28
PL2341927T3 (pl)	2016-11-30
CA2739387A1 (en)	2010-04-08
ES2607460T3 (es)	2017-03-31
WO2010037514A3 (en)	2010-06-03
EA032437B1 (ru)	2019-05-31
PT2341927T (pt)	2016-08-02
KR20200085381A (ko)	2020-07-14
CY1123526T1 (el)	2022-03-24
KR102133402B1 (ko)	2020-07-14
US20120141517A1 (en)	2012-06-07
HRP20190202T1 (hr)	2019-03-22
US20160376313A1 (en)	2016-12-29
CN102170900B (zh)	2016-10-26
RS60385B1 (sr)	2020-07-31
US20190010190A1 (en)	2019-01-10
CY1122677T1 (el)	2021-03-12
US20150125478A1 (en)	2015-05-07
JP2017029135A (ja)	2017-02-09
JP2017023136A (ja)	2017-02-02
KR20160103558A (ko)	2016-09-01
US8653035B2 (en)	2014-02-18
EP3120870A1 (en)	2017-01-25
JP2016145210A (ja)	2016-08-12
CN106986919A (zh)	2017-07-28
BRPI0920791A2 (pt)	2019-12-10
CY1123113T1 (el)	2021-10-29
ES2584245T3 (es)	2016-09-26
EP2341927B1 (en)	2016-05-04
EP3111952A1 (en)	2017-01-04
DK3069728T3 (en)	2019-02-25
BRPI0920791B1 (pt)	2022-01-18
UA103202C2 (ru)	2013-09-25
KR101756488B1 (ko)	2017-07-11
PT3120868T (pt)	2020-07-16
PL3111952T3 (pl)	2019-04-30
CA2936869C (en)	2019-08-06
DK2341927T3 (da)	2016-08-15
JP2012504393A (ja)	2012-02-23
KR20110074894A (ko)	2011-07-04
US20160376315A1 (en)	2016-12-29
US10047123B2 (en)	2018-08-14
SI3106175T1 (sl)	2020-08-31
JP2017000148A (ja)	2017-01-05
LT3120870T (lt)	2020-08-10
SI2172211T1 (sl)	2015-03-31
US10047124B2 (en)	2018-08-14
CA2739387C (en)	2019-10-29
PL3069728T3 (pl)	2019-05-31
PL3120869T3 (pl)	2021-01-25
EA201100586A1 (ru)	2011-10-31
US10919931B2 (en)	2021-02-16
SI2331118T1 (sl)	2017-01-31
US20160376314A1 (en)	2016-12-29
NZ591855A (en)	2012-11-30
RS60006B1 (sr)	2020-04-30
RS60656B1 (sr)	2020-09-30
DK2331118T5 (en)	2017-06-19
ES2802226T3 (es)	2021-01-18
EA023013B1 (ru)	2016-04-29
JP5883476B2 (ja)	2016-03-15
RS60381B1 (sr)	2020-07-31
US20160376316A1 (en)	2016-12-29
RS60386B1 (sr)	2020-07-31
UA110599C2 (uk)	2016-01-25
CY1116302T1 (el)	2017-02-08
SI3120870T1 (sl)	2020-08-31
ES2708654T3 (es)	2019-04-10
CY1121258T1 (el)	2020-05-29
EP3120868A1 (en)	2017-01-25
US10906936B2 (en)	2021-02-02
EP2172212A3 (en)	2010-04-14
PL3106175T3 (pl)	2020-08-24
SI3124043T1 (sl)	2020-07-31
JP2017018102A (ja)	2017-01-26
JP5855940B2 (ja)	2016-02-09
DK3120870T3 (da)	2020-06-22
LT3120868T (lt)	2020-08-10
CY1123098T1 (el)	2021-10-29
EP3111952B1 (en)	2018-10-31
US8119139B2 (en)	2012-02-21
BRPI0920759A2 (pt)	2016-03-08
RS55043B1 (sr)	2016-12-30
US8318677B2 (en)	2012-11-27
US20210347822A1 (en)	2021-11-11
ES2788129T8 (es)	2020-11-04
HRP20201015T1 (hr)	2020-10-16
ES2612466T3 (es)	2017-05-17
KR101687840B1 (ko)	2016-12-19
EA023378B1 (ru)	2016-05-31
EA201100587A1 (ru)	2011-10-31
HUE050428T2 (hu)	2020-12-28
NZ603016A (en)	2014-05-30
ES2788129T3 (es)	2020-10-20
HRP20201025T1 (hr)	2020-12-25
US12221493B2 (en)	2025-02-11
EP2172212A2 (en)	2010-04-07
LT3111952T (lt)	2018-12-27
HK1161106A1 (en)	2012-08-24
PL3132801T3 (pl)	2020-06-15
MX2011003539A (es)	2011-06-20
EP3120868B1 (en)	2020-04-08
HK1159526A1 (zh)	2012-08-03
CA2936982A1 (en)	2010-04-08
EP3069728B1 (en)	2018-11-14
HUE041446T2 (hu)	2019-05-28
SI3132801T1 (sl)	2020-03-31
KR102392070B1 (ko)	2022-04-29
PL3120868T3 (pl)	2020-08-24
HRP20200722T1 (hr)	2020-10-16
PT2172212T (pt)	2016-12-22
ES2819244T3 (es)	2021-04-15
JP2012504563A (ja)	2012-02-23
KR101883426B1 (ko)	2018-07-31
PT3111952T (pt)	2019-02-05
HRP20150223T8 (hr)	2015-07-03
PL2172211T3 (pl)	2015-05-29
EP2172211A1 (en)	2010-04-07
CA2936868C (en)	2019-10-22
CA2739384C (en)	2017-05-02
CN102170901A (zh)	2011-08-31
PL3124043T3 (pl)	2020-07-27
HRP20201025T8 (hr)	2022-01-07
JP6214066B2 (ja)	2017-10-18
US10227381B2 (en)	2019-03-12
CY1123089T1 (el)	2021-10-29
EP3132801B1 (en)	2019-10-30
LT3124043T (lt)	2020-07-10
US20160376312A1 (en)	2016-12-29
JP2017018101A (ja)	2017-01-26
KR20220058655A (ko)	2022-05-09

Publication	Publication Date	Title
DK2331118T3 (da)	2017-01-09	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
PL2567707T3 (pl)	2017-03-31	Kompozycja peptydów związanych z guzem i pokrewna szczepionka przeciw rakowi
IL276157A (en)	2020-09-30	Pharmaceutical preparations and methods for transferring them related to them
PL2547691T3 (pl)	2016-12-30	Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia raka żołądka i innych rodzajów raka
PL3023788T3 (pl)	2020-07-27	Kompozycje neoantygenów specyficznych wobec nowotworu do zastosowania w leczeniu nowotworów
IL220386B (en)	2020-04-30	Compositions for the liquidation of tumors and uses thereof
PL3363456T3 (pl)	2021-05-04	Nowa immunoterapia względem wielu nowotworów, w tym raka układu trawiennego i raka żołądka
IL236516B (en)	2018-05-31	Antibodies and compositions comprising them for treatment of cancer
LTC2152290I2 (lt)	2018-12-27	Anti-il-5 antikūnų skyrimo būdai
EP2002263A4 (en)	2009-10-28	IMMUNOTHERAPY COMPOSITIONS FOR CANCER AND METHODS OF USE
BR112012018947A2 (pt)	2017-06-27	composição farmacêutica para tratamento e\ou prevenção do cancêr
DK2322221T3 (da)	2014-09-01	Farmaceutisk sammensætning til behandling og forebyggelse af cancer
BRPI0915928A2 (pt)	2015-11-03	composições e métodos de uso para anticorpos terapêuticos
DK2340042T3 (da)	2014-10-27	Fremgangsmåder og præparater til behandling af cancer
EP2591799A4 (en)	2014-06-11	CANCER PEPTIDE VACCINE
DK2331092T3 (da)	2014-05-19	Fremgangsmåder og sammensætninger til indgivelse af 3-halopyruvat og associerede forbindelser til behandling af cancer
TH100308B (th)	2010-02-26	สารเตรียมของแข็งทางเภสัชภัณฑ์และวิธีการผลิตสิ่งดังกล่าว